Yutaka Koyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yutaka Koyama has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Shotaro Michinaga
Department of Pharmacodynamics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan
8 shared publications Shotaro Michinaga
Department of Pharmacodynamics, Meiji Pharmaceutical University, Tokyo, Japan
4 shared publications- Yasuhiko Izumi
Laboratory of Pharmacology, Kobe Pharmaceutical University, Kobe, Japan
4 shared publications Hiroyuki Mizuguchi
Laboratory of Pharmacology, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 Nishikiori-Kita, Tondabayashi, Osaka, 584-8540, Japan
3 shared publications- Shigeru Hishinuma
Department of Pharmacodynamics, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan
3 shared publications Akemichi Baba
Laboratory of Molecular Neuropharmacology Graduate School of Pharmaceutical Sciences,Osaka University,Yamada-Oka 1-6,Suita 565-0871,Japan
2 shared publications
Latest Publications
- 27 July 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1031
PNU-120596, an α7 nicotinic acetylcholine receptor positive allosteric modulator, attenuates microglial activation and protects dopaminergic neurons from inflammatory injury independently of canonical α7 nicotinic acetylcholine receptor signaling
- 27 July 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1031
PNU-120596, an α7 nicotinic acetylcholine receptor positive allosteric modulator, attenuates microglial activation and protects dopaminergic neurons from inflammatory injury independently of canonical α7 nicotinic acetylcholine receptor signaling
- Open Access
- 2 April 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (5) , 111424
Endothelin-1 induces Zfp36 family RNA-binding proteins and restrains cytokine and chemokine production in reactive astrocytes
- 2 April 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (5) , 111424
Open AccessEndothelin-1 induces Zfp36 family RNA-binding proteins and restrains cytokine and chemokine production in reactive astrocytes
- Open Access
- 13 December 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (12) , 1527
Nrf2-Independent Anti-Inflammatory Effects of Dimethyl Fumarate: Challenges and Prospects in Developing Electrophilic Nrf2 Activators for Neurodegenerative Diseases
The NF-E2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway is a potential therapeutic target for central nervous system diseases. This review emphasizes the role of oxidative stress and neuroinflammation in neurodegenerative diseases, highlighting the therapeutic potential of Nrf2 activators such as dimethyl fumarate (DMF). DMF, initially administered for treating psoriasis, has demonstrated efficacy in multiple sclerosis and is metabolized to monomethyl fumarate, which may exert significant therapeutic effects. DMF activates the Nrf2-ARE pathway, and recent studies have indicated that its anti-inflammatory effects occur through Nrf2-independent mechanisms. Electrophilic Nrf2 activators, such as DMF, covalently bind to cysteine residues in proteins and modulate their function. We discuss the implications of cysteine residue modifications by DMF, which may cause both therapeutic benefits and potential off-target effects. Furthermore, we propose a chemical proteomics-based drug discovery approach to achieve desired therapeutic effects by selectively covalently modifying cysteines in target proteins. These findings advocate for a broader understanding of the Nrf2-independent mechanisms of electrophilic Nrf2 activators, thereby improving drug discovery strategies that target neurodegenerative diseases while minimizing toxicity.
- 13 December 2024
- Published by MDPI AG in Antioxidants
- Vol. 13 (12) , 1527
Open AccessNrf2-Independent Anti-Inflammatory Effects of Dimethyl Fumarate: Challenges and Prospects in Developing Electrophilic Nrf2 Activators for Neurodegenerative Diseases
The NF-E2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway is a potential therapeutic target for central nervous system diseases. This review emphasizes the role of oxidative stress and neuroinflammation in neurodegenerative diseases, highlighting the therapeutic potential of Nrf2 activators such as dimethyl fumarate (DMF). DMF, initially administered for treating psoriasis, has demonstrated efficacy in multiple sclerosis and is metabolized to monomethyl fumarate, which may exert significant therapeutic effects. DMF activates the Nrf2-ARE pathway, and recent studies have indicated that its anti-inflammatory effects occur through Nrf2-independent mechanisms. Electrophilic Nrf2 activators, such as DMF, covalently bind to cysteine residues in proteins and modulate their function. We discuss the implications of cysteine residue modifications by DMF, which may cause both therapeutic benefits and potential off-target effects. Furthermore, we propose a chemical proteomics-based drug discovery approach to achieve desired therapeutic effects by selectively covalently modifying cysteines in target proteins. These findings advocate for a broader understanding of the Nrf2-independent mechanisms of electrophilic Nrf2 activators, thereby improving drug discovery strategies that target neurodegenerative diseases while minimizing toxicity.
Endothelin‐1 increases Na + ‐K + ‐ 2Cl − cotransporter‐1 expression in cultured astrocytes and in traumatic brain injury model: An involvement of HIF1α activation
Na + ‐K + ‐2Cl − cotransporter‐1 (NKCC1) is present in brain cells, including astrocytes. The expression of astrocytic NKCC1 increases in the acute phase of traumatic brain injury (TBI), which induces brain edema. Endothelin‐1 (ET‐1) is a factor that induces brain edema and regulates the expression of several pathology‐related genes in astrocytes. In the present study, we investigated the effect of ET‐1 on NKCC1 expression in astrocytes. ET‐1 (100 nM)‐treated cultured astrocytes showed increased NKCC1 mRNA and protein levels. The effect of ET‐1 on NKCC1 expression in cultured astrocytes was reduced by BQ788 (1 μM), an ET B antagonist, but not by FR139317 (1 μM), an ET A antagonist. The involvement of ET‐1 in NKCC1 expression in TBI was examined using a fluid percussion injury (FPI) mouse model that replicates the pathology of TBI with high reproducibility. Administration of BQ788 (15 nmol/day) decreased FPI‐induced expressions of NKCC1 mRNA and protein, accompanied with a reduction of astrocytic activation. FPI‐induced brain edema was attenuated by BQ788 and NKCC1 inhibitors (azosemide and bumetanide). ET‐1‐treated cultured astrocytes showed increased mRNA and protein expression of hypoxia‐inducible factor‐1α (HIF1α). Immunohistochemical observations of mouse cerebrum after FPI showed co‐localization of HIF1α with GFAP‐positive astrocytes. Increased HIF1α expression in the TBI model was reversed by BQ788. FM19G11 (an HIF inhibitor, 1 μM) and HIF1α siRNA suppressed ET‐induced increase in NKCC1 expression in cultured astrocytes. These results indicate that ET‐1 increases NKCC1 expression in astrocytes through the activation of HIF1α.
Endothelin‐1 increases Na + ‐K + ‐ 2Cl − cotransporter‐1 expression in cultured astrocytes and in traumatic brain injury model: An involvement of HIF1α activation
Na + ‐K + ‐2Cl − cotransporter‐1 (NKCC1) is present in brain cells, including astrocytes. The expression of astrocytic NKCC1 increases in the acute phase of traumatic brain injury (TBI), which induces brain edema. Endothelin‐1 (ET‐1) is a factor that induces brain edema and regulates the expression of several pathology‐related genes in astrocytes. In the present study, we investigated the effect of ET‐1 on NKCC1 expression in astrocytes. ET‐1 (100 nM)‐treated cultured astrocytes showed increased NKCC1 mRNA and protein levels. The effect of ET‐1 on NKCC1 expression in cultured astrocytes was reduced by BQ788 (1 μM), an ET B antagonist, but not by FR139317 (1 μM), an ET A antagonist. The involvement of ET‐1 in NKCC1 expression in TBI was examined using a fluid percussion injury (FPI) mouse model that replicates the pathology of TBI with high reproducibility. Administration of BQ788 (15 nmol/day) decreased FPI‐induced expressions of NKCC1 mRNA and protein, accompanied with a reduction of astrocytic activation. FPI‐induced brain edema was attenuated by BQ788 and NKCC1 inhibitors (azosemide and bumetanide). ET‐1‐treated cultured astrocytes showed increased mRNA and protein expression of hypoxia‐inducible factor‐1α (HIF1α). Immunohistochemical observations of mouse cerebrum after FPI showed co‐localization of HIF1α with GFAP‐positive astrocytes. Increased HIF1α expression in the TBI model was reversed by BQ788. FM19G11 (an HIF inhibitor, 1 μM) and HIF1α siRNA suppressed ET‐induced increase in NKCC1 expression in cultured astrocytes. These results indicate that ET‐1 increases NKCC1 expression in astrocytes through the activation of HIF1α.
- 19 May 2024
- Published by Elsevier
- Vol. 126, 97-111
Roles of astrocytic sonic hedgehog production and its signal for regulation of the blood-brain barrier permeability
- 19 May 2024
- Published by Elsevier
- Vol. 126, 97-111
Roles of astrocytic sonic hedgehog production and its signal for regulation of the blood-brain barrier permeability
- Open Access
Roles of Astrocytic Endothelin ETB Receptor in Traumatic Brain Injury
Traumatic brain injury (TBI) is an intracranial injury caused by accidents, falls, or sports. The production of endothelins (ETs) is increased in the injured brain. ET receptors are classified into distinct types, including ETA receptor (ETA-R) and ETB receptor (ETB-R). ETB-R is highly expressed in reactive astrocytes and upregulated by TBI. Activation of astrocytic ETB-R promotes conversion to reactive astrocytes and the production of astrocyte-derived bioactive factors, including vascular permeability regulators and cytokines, which cause blood–brain barrier (BBB) disruption, brain edema, and neuroinflammation in the acute phase of TBI. ETB-R antagonists alleviate BBB disruption and brain edema in animal models of TBI. The activation of astrocytic ETB receptors also enhances the production of various neurotrophic factors. These astrocyte-derived neurotrophic factors promote the repair of the damaged nervous system in the recovery phase of patients with TBI. Thus, astrocytic ETB-R is expected to be a promising drug target for TBI in both the acute and recovery phases. This article reviews recent observations on the role of astrocytic ETB receptors in TBI.
Open AccessRoles of Astrocytic Endothelin ETB Receptor in Traumatic Brain Injury
Traumatic brain injury (TBI) is an intracranial injury caused by accidents, falls, or sports. The production of endothelins (ETs) is increased in the injured brain. ET receptors are classified into distinct types, including ETA receptor (ETA-R) and ETB receptor (ETB-R). ETB-R is highly expressed in reactive astrocytes and upregulated by TBI. Activation of astrocytic ETB-R promotes conversion to reactive astrocytes and the production of astrocyte-derived bioactive factors, including vascular permeability regulators and cytokines, which cause blood–brain barrier (BBB) disruption, brain edema, and neuroinflammation in the acute phase of TBI. ETB-R antagonists alleviate BBB disruption and brain edema in animal models of TBI. The activation of astrocytic ETB receptors also enhances the production of various neurotrophic factors. These astrocyte-derived neurotrophic factors promote the repair of the damaged nervous system in the recovery phase of patients with TBI. Thus, astrocytic ETB-R is expected to be a promising drug target for TBI in both the acute and recovery phases. This article reviews recent observations on the role of astrocytic ETB receptors in TBI.
- Open Access
- 20 April 2022
- Published by Springer Nature in Research Square
TPNA10168, an Nrf-2 activator, stimulates glutathione production by inducing system Xc-, and g-glutamate cysteine ligase subunits in cultured mouse astrocytes.
Nuclear factor-erythroid 2-related factor 2 (Nrf-2) is a transcription factor involved in cellular defense mechanisms against oxidative stress and mediates the expression of various antioxidant-related molecules. We previously showed that TPNA10168, a novel Nrf-2 activator, has neuroprotective effects. To elucidate the mechanisms underlying the cytoprotective action of TPNA10168, its effects on the expression of glutathione biosynthesis-related molecules in cultured mouse astrocytes were examined. Cultured astrocytes were prepared from the cerebra of 1-day-old C57BL/6N mice. mRNA and protein levels were measured by quantitative PCR and immunoblotting, respectively. Treatment with TPNA10168 (30 µM) increased the astrocytic Nrf-2 protein level. Nuclear translocation of Nrf-2 and its binding to the Nrf-2 recognition DNA fragment were stimulated by TPNA10168. The mRNA and protein levels of system Xc−, a cystine/glutamate exchange transporter, in cultured astrocytes were increased by TPNA10168. TPNA10168 also increased the expression of γ-glutamate cysteine ligase subunits (γ-GCLm and γ-GCLc). Accompanied by the increased expression of system Xc−, γ-GCLm, and γ-GCLc, the production of astrocytic glutathione was increased by TPNA10168. The effects of TPNA10168 on the expression of system Xc−, γ-GCLm, and γ-GCLc were reduced by the Nrf-2 inhibitor ML385 (10 µM). Rotenone (2.5 nM) induced cell death in cultured astrocytes; however, this effect was alleviated by TPNA10168. The results suggest that Nrf-2-mediated astrocytic glutathione biosynthesis is one of the mechanisms underlying the cytoprotective action of TPNA10168.
- 20 April 2022
- Published by Springer Nature in Research Square
Open AccessTPNA10168, an Nrf-2 activator, stimulates glutathione production by inducing system Xc-, and g-glutamate cysteine ligase subunits in cultured mouse astrocytes.
Nuclear factor-erythroid 2-related factor 2 (Nrf-2) is a transcription factor involved in cellular defense mechanisms against oxidative stress and mediates the expression of various antioxidant-related molecules. We previously showed that TPNA10168, a novel Nrf-2 activator, has neuroprotective effects. To elucidate the mechanisms underlying the cytoprotective action of TPNA10168, its effects on the expression of glutathione biosynthesis-related molecules in cultured mouse astrocytes were examined. Cultured astrocytes were prepared from the cerebra of 1-day-old C57BL/6N mice. mRNA and protein levels were measured by quantitative PCR and immunoblotting, respectively. Treatment with TPNA10168 (30 µM) increased the astrocytic Nrf-2 protein level. Nuclear translocation of Nrf-2 and its binding to the Nrf-2 recognition DNA fragment were stimulated by TPNA10168. The mRNA and protein levels of system Xc−, a cystine/glutamate exchange transporter, in cultured astrocytes were increased by TPNA10168. TPNA10168 also increased the expression of γ-glutamate cysteine ligase subunits (γ-GCLm and γ-GCLc). Accompanied by the increased expression of system Xc−, γ-GCLm, and γ-GCLc, the production of astrocytic glutathione was increased by TPNA10168. The effects of TPNA10168 on the expression of system Xc−, γ-GCLm, and γ-GCLc were reduced by the Nrf-2 inhibitor ML385 (10 µM). Rotenone (2.5 nM) induced cell death in cultured astrocytes; however, this effect was alleviated by TPNA10168. The results suggest that Nrf-2-mediated astrocytic glutathione biosynthesis is one of the mechanisms underlying the cytoprotective action of TPNA10168.
- Top Cited PapersOpen Access
- 15 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (12) , 6418
Pathophysiological Responses and Roles of Astrocytes in Traumatic Brain Injury
Traumatic brain injury (TBI) is immediate damage caused by a blow to the head resulting from traffic accidents, falls, and sporting activity, which causes death or serious disabilities in survivors. TBI induces multiple secondary injuries, including neuroinflammation, disruption of the blood–brain barrier (BBB), and brain edema. Despite these emergent conditions, current therapies for TBI are limited or insufficient in some cases. Although several candidate drugs exerted beneficial effects in TBI animal models, most of them failed to show significant effects in clinical trials. Multiple studies have suggested that astrocytes play a key role in the pathogenesis of TBI. Increased reactive astrocytes and astrocyte-derived factors are commonly observed in both TBI patients and experimental animal models. Astrocytes have beneficial and detrimental effects on TBI, including promotion and restriction of neurogenesis and synaptogenesis, acceleration and suppression of neuroinflammation, and disruption and repair of the BBB via multiple bioactive factors. Additionally, astrocytic aquaporin-4 is involved in the formation of cytotoxic edema. Thus, astrocytes are attractive targets for novel therapeutic drugs for TBI, although astrocyte-targeting drugs have not yet been developed. This article reviews recent observations of the roles of astrocytes and expected astrocyte-targeting drugs in TBI.
- 15 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (12) , 6418
Top Cited PapersOpen AccessPathophysiological Responses and Roles of Astrocytes in Traumatic Brain Injury
Traumatic brain injury (TBI) is immediate damage caused by a blow to the head resulting from traffic accidents, falls, and sporting activity, which causes death or serious disabilities in survivors. TBI induces multiple secondary injuries, including neuroinflammation, disruption of the blood–brain barrier (BBB), and brain edema. Despite these emergent conditions, current therapies for TBI are limited or insufficient in some cases. Although several candidate drugs exerted beneficial effects in TBI animal models, most of them failed to show significant effects in clinical trials. Multiple studies have suggested that astrocytes play a key role in the pathogenesis of TBI. Increased reactive astrocytes and astrocyte-derived factors are commonly observed in both TBI patients and experimental animal models. Astrocytes have beneficial and detrimental effects on TBI, including promotion and restriction of neurogenesis and synaptogenesis, acceleration and suppression of neuroinflammation, and disruption and repair of the BBB via multiple bioactive factors. Additionally, astrocytic aquaporin-4 is involved in the formation of cytotoxic edema. Thus, astrocytes are attractive targets for novel therapeutic drugs for TBI, although astrocyte-targeting drugs have not yet been developed. This article reviews recent observations of the roles of astrocytes and expected astrocyte-targeting drugs in TBI.
- Open Access
- 21 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (9) , 4333
Endothelin ETB Receptor-Mediated Astrocytic Activation: Pathological Roles in Brain Disorders
In brain disorders, reactive astrocytes, which are characterized by hypertrophy of the cell body and proliferative properties, are commonly observed. As reactive astrocytes are involved in the pathogenesis of several brain disorders, the control of astrocytic function has been proposed as a therapeutic strategy, and target molecules to effectively control astrocytic functions have been investigated. The production of brain endothelin-1 (ET-1), which increases in brain disorders, is involved in the pathophysiological response of the nervous system. Endothelin B (ETB) receptors are highly expressed in reactive astrocytes and are upregulated by brain injury. Activation of astrocyte ETB receptors promotes the induction of reactive astrocytes. In addition, the production of various astrocyte-derived factors, including neurotrophic factors and vascular permeability regulators, is regulated by ETB receptors. In animal models of Alzheimer’s disease, brain ischemia, neuropathic pain, and traumatic brain injury, ETB-receptor-mediated regulation of astrocytic activation has been reported to improve brain disorders. Therefore, the astrocytic ETB receptor is expected to be a promising drug target to improve several brain disorders. This article reviews the roles of ETB receptors in astrocytic activation and discusses its possible applications in the treatment of brain disorders.
- 21 April 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (9) , 4333
Open AccessEndothelin ETB Receptor-Mediated Astrocytic Activation: Pathological Roles in Brain Disorders
In brain disorders, reactive astrocytes, which are characterized by hypertrophy of the cell body and proliferative properties, are commonly observed. As reactive astrocytes are involved in the pathogenesis of several brain disorders, the control of astrocytic function has been proposed as a therapeutic strategy, and target molecules to effectively control astrocytic functions have been investigated. The production of brain endothelin-1 (ET-1), which increases in brain disorders, is involved in the pathophysiological response of the nervous system. Endothelin B (ETB) receptors are highly expressed in reactive astrocytes and are upregulated by brain injury. Activation of astrocyte ETB receptors promotes the induction of reactive astrocytes. In addition, the production of various astrocyte-derived factors, including neurotrophic factors and vascular permeability regulators, is regulated by ETB receptors. In animal models of Alzheimer’s disease, brain ischemia, neuropathic pain, and traumatic brain injury, ETB-receptor-mediated regulation of astrocytic activation has been reported to improve brain disorders. Therefore, the astrocytic ETB receptor is expected to be a promising drug target to improve several brain disorders. This article reviews the roles of ETB receptors in astrocytic activation and discusses its possible applications in the treatment of brain disorders.